OBJECTIVE: This study was intended to assess the extent to which the low-expression alleles of the serotonin transporter gene promoter predict poor response to cognitive behavior therapy in patients with posttraumatic stress disorder (PTSD). METHOD: Forty-five patients with PTSD underwent an 8-week exposure-based cognitive behavior therapy program and provided mouth swabs or saliva samples to extract genomic DNA and classify individuals according to four allelic forms (S(A), S(G), L(A), L(G)) of the 5-HTT-linked polymorphic region (5-HTTLPR). We determined whether the 5-HTTLPR genotype predicted change in PTSD severity following treatment (n = 45) and 6 months later (n = 42). RESULTS: After controlling for pretreatment PTSD severity and number of treatment sessions, the 5-HTTLPR low-expression genotype group (S or L(G) allele carriers) displayed more severe PTSD 6 months following treatment relative to other patients. CONCLUSIONS: This study suggests a genetic contribution to treatment outcome following cognitive behavior therapy and implicates the serotonergic system in response to exposure-based treatments in PTSD.
OBJECTIVE: This study was intended to assess the extent to which the low-expression alleles of the serotonin transporter gene promoter predict poor response to cognitive behavior therapy in patients with posttraumatic stress disorder (PTSD). METHOD: Forty-five patients with PTSD underwent an 8-week exposure-based cognitive behavior therapy program and provided mouth swabs or saliva samples to extract genomic DNA and classify individuals according to four allelic forms (S(A), S(G), L(A), L(G)) of the 5-HTT-linked polymorphic region (5-HTTLPR). We determined whether the 5-HTTLPR genotype predicted change in PTSD severity following treatment (n = 45) and 6 months later (n = 42). RESULTS: After controlling for pretreatment PTSD severity and number of treatment sessions, the 5-HTTLPR low-expression genotype group (S or L(G) allele carriers) displayed more severe PTSD 6 months following treatment relative to other patients. CONCLUSIONS: This study suggests a genetic contribution to treatment outcome following cognitive behavior therapy and implicates the serotonergic system in response to exposure-based treatments in PTSD.
Authors: Nathan A Kimbrel; Sandra B Morissette; Eric C Meyer; Roberta Chrestman; Robert Jamroz; Paul J Silvia; Jean C Beckham; Keith A Young Journal: Anxiety Stress Coping Date: 2014-11-14
Authors: Andrew T Gloster; Alexander L Gerlach; Alfons Hamm; Michael Höfler; Georg W Alpers; Tilo Kircher; Andreas Ströhle; Thomas Lang; Hans-Ulrich Wittchen; Jürgen Deckert; Andreas Reif Journal: Eur Arch Psychiatry Clin Neurosci Date: 2015-01-15 Impact factor: 5.270
Authors: Michael B VanElzakker; M Kathryn Dahlgren; F Caroline Davis; Stacey Dubois; Lisa M Shin Journal: Neurobiol Learn Mem Date: 2013-12-07 Impact factor: 2.877
Authors: Anne N Banducci; Melissa Gomes; Laura MacPherson; C W Lejuez; Marc N Potenza; Joel Gelernter; Ananda B Amstadter Journal: Psychol Trauma Date: 2014-01-01
Authors: Tina B Lonsdorf; Christian Rück; Jan Bergström; Gerhard Andersson; Arne Ohman; Nils Lindefors; Martin Schalling Journal: BMC Psychiatry Date: 2010-11-26 Impact factor: 3.630
Authors: Kim L Felmingham; Carol Dobson-Stone; Peter R Schofield; Gregory J Quirk; Richard A Bryant Journal: Biol Psychiatry Date: 2013-01-08 Impact factor: 13.382